Titre : Interleukine-27

Interleukine-27 : Questions médicales fréquentes

Termes MeSH sélectionnés :

Complement Inactivating Agents
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Interleukine-27 : Questions médicales les plus fréquentes", "headline": "Interleukine-27 : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Interleukine-27 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-02-24", "dateModified": "2025-05-19", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Interleukine-27" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Interleukines", "url": "https://questionsmedicales.fr/mesh/D007378", "about": { "@type": "MedicalCondition", "name": "Interleukines", "code": { "@type": "MedicalCode", "code": "D007378", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D23.529.374.465" } } }, "about": { "@type": "MedicalCondition", "name": "Interleukine-27", "alternateName": "Interleukin-27", "code": { "@type": "MedicalCode", "code": "D064094", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Cory M Robinson", "url": "https://questionsmedicales.fr/author/Cory%20M%20Robinson", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Tomozumi Imamichi", "url": "https://questionsmedicales.fr/author/Tomozumi%20Imamichi", "affiliation": { "@type": "Organization", "name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA." } }, { "@type": "Person", "name": "Jessica M Povroznik", "url": "https://questionsmedicales.fr/author/Jessica%20M%20Povroznik", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Jordan K Vance", "url": "https://questionsmedicales.fr/author/Jordan%20K%20Vance", "affiliation": { "@type": "Organization", "name": "Department of Microbiology, Immunology, & Cell Biology, West Virginia University School of Medicine, Morgantown, WV, United States." } }, { "@type": "Person", "name": "Xiaojun Hu", "url": "https://questionsmedicales.fr/author/Xiaojun%20Hu", "affiliation": { "@type": "Organization", "name": "Laboratory of Human Retrovirology and Immunoinformatics, Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Anti-C1s humanized monoclonal antibody SAR445088: A classical pathway complement inhibitor specific for the active form of C1s.", "datePublished": "2023-05-04", "url": "https://questionsmedicales.fr/article/37149117", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.clim.2023.109629" } }, { "@type": "ScholarlyArticle", "name": "Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.", "datePublished": "2023-01-14", "url": "https://questionsmedicales.fr/article/36732204", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.blre.2023.101041" } }, { "@type": "ScholarlyArticle", "name": "Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.", "datePublished": "2023-04-18", "url": "https://questionsmedicales.fr/article/37072660", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1007/s12325-023-02510-4" } }, { "@type": "ScholarlyArticle", "name": "Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.", "datePublished": "2022-08-09", "url": "https://questionsmedicales.fr/article/35945604", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1186/s12931-022-02126-2" } }, { "@type": "ScholarlyArticle", "name": "Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.", "datePublished": "2022-10-06", "url": "https://questionsmedicales.fr/article/36201560", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1371/journal.pntd.0010809" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Facteurs biologiques", "item": "https://questionsmedicales.fr/mesh/D001685" }, { "@type": "ListItem", "position": 3, "name": "Protéines et peptides de signalisation intercellulaire", "item": "https://questionsmedicales.fr/mesh/D036341" }, { "@type": "ListItem", "position": 4, "name": "Cytokines", "item": "https://questionsmedicales.fr/mesh/D016207" }, { "@type": "ListItem", "position": 5, "name": "Interleukines", "item": "https://questionsmedicales.fr/mesh/D007378" }, { "@type": "ListItem", "position": 6, "name": "Interleukine-27", "item": "https://questionsmedicales.fr/mesh/D064094" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Interleukine-27 - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Interleukine-27", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-19", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Interleukine-27", "description": "Comment mesurer l'IL-27 dans le sang ?\nQuels tests sont utilisés pour évaluer l'IL-27 ?\nL'IL-27 est-elle mesurée dans des maladies spécifiques ?\nQuels biomarqueurs sont associés à l'IL-27 ?\nL'IL-27 peut-elle être un indicateur de gravité ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+Inactivating+Agents&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Interleukine-27", "description": "Quels symptômes sont liés à une élévation de l'IL-27 ?\nL'IL-27 est-elle liée à des douleurs articulaires ?\nQuels signes cliniques sont associés à l'IL-27 ?\nL'IL-27 influence-t-elle les symptômes respiratoires ?\nY a-t-il des symptômes neurologiques liés à l'IL-27 ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+Inactivating+Agents&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Interleukine-27", "description": "Peut-on prévenir l'élévation de l'IL-27 ?\nY a-t-il des vaccins liés à l'IL-27 ?\nComment l'alimentation influence-t-elle l'IL-27 ?\nL'exercice physique affecte-t-il l'IL-27 ?\nLe sommeil influence-t-il l'IL-27 ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+Inactivating+Agents&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Interleukine-27", "description": "Quels traitements ciblent l'IL-27 ?\nL'IL-27 peut-elle être inhibée ?\nQuels médicaments affectent l'IL-27 ?\nL'IL-27 est-elle une cible pour l'immunothérapie ?\nComment l'IL-27 influence-t-elle les traitements ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+Inactivating+Agents&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Interleukine-27", "description": "Quelles complications sont liées à l'IL-27 ?\nL'IL-27 est-elle impliquée dans des maladies chroniques ?\nComment l'IL-27 affecte-t-elle le cancer ?\nY a-t-il des risques d'infection liés à l'IL-27 ?\nL'IL-27 est-elle liée à des troubles neurologiques ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+Inactivating+Agents&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Interleukine-27", "description": "Quels facteurs augmentent l'IL-27 ?\nL'âge influence-t-il les niveaux d'IL-27 ?\nLes maladies auto-immunes sont-elles un facteur de risque ?\nLe tabagisme affecte-t-il l'IL-27 ?\nY a-t-il un lien entre l'IL-27 et l'alimentation ?", "url": "https://questionsmedicales.fr/mesh/D064094?mesh_terms=Complement+Inactivating+Agents&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment mesurer l'IL-27 dans le sang ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut être mesurée par des tests ELISA dans des échantillons de sérum." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'IL-27 ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des tests immunologiques comme l'ELISA et la cytométrie en flux sont utilisés." } }, { "@type": "Question", "name": "L'IL-27 est-elle mesurée dans des maladies spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est souvent mesurée dans des maladies auto-immunes et inflammatoires." } }, { "@type": "Question", "name": "Quels biomarqueurs sont associés à l'IL-27 ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 est souvent associée à d'autres cytokines comme l'IL-6 et l'IL-10." } }, { "@type": "Question", "name": "L'IL-27 peut-elle être un indicateur de gravité ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux élevés d'IL-27 peuvent indiquer une inflammation sévère." } }, { "@type": "Question", "name": "Quels symptômes sont liés à une élévation de l'IL-27 ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Une élévation de l'IL-27 peut entraîner des symptômes d'inflammation comme la fièvre." } }, { "@type": "Question", "name": "L'IL-27 est-elle liée à des douleurs articulaires ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 peut contribuer à des douleurs articulaires dans les maladies inflammatoires." } }, { "@type": "Question", "name": "Quels signes cliniques sont associés à l'IL-27 ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes cliniques incluent fatigue, douleurs et symptômes systémiques d'inflammation." } }, { "@type": "Question", "name": "L'IL-27 influence-t-elle les symptômes respiratoires ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 peut exacerber les symptômes respiratoires dans certaines maladies pulmonaires." } }, { "@type": "Question", "name": "Y a-t-il des symptômes neurologiques liés à l'IL-27 ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent être associés à des symptômes neurologiques dans certaines conditions." } }, { "@type": "Question", "name": "Peut-on prévenir l'élévation de l'IL-27 ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Des modes de vie sains et une gestion du stress peuvent aider à prévenir l'élévation de l'IL-27." } }, { "@type": "Question", "name": "Y a-t-il des vaccins liés à l'IL-27 ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Actuellement, il n'existe pas de vaccins spécifiquement ciblant l'IL-27." } }, { "@type": "Question", "name": "Comment l'alimentation influence-t-elle l'IL-27 ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Une alimentation anti-inflammatoire peut aider à réguler les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'exercice physique affecte-t-il l'IL-27 ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exercice régulier peut réduire les niveaux d'IL-27 et améliorer la santé immunitaire." } }, { "@type": "Question", "name": "Le sommeil influence-t-il l'IL-27 ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Un sommeil adéquat est crucial pour maintenir des niveaux sains d'IL-27 et une bonne santé." } }, { "@type": "Question", "name": "Quels traitements ciblent l'IL-27 ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies biologiques ciblant l'IL-27 sont en développement pour les maladies auto-immunes." } }, { "@type": "Question", "name": "L'IL-27 peut-elle être inhibée ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des inhibiteurs spécifiques de l'IL-27 sont à l'étude pour réduire l'inflammation." } }, { "@type": "Question", "name": "Quels médicaments affectent l'IL-27 ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Certains médicaments anti-inflammatoires peuvent moduler les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'IL-27 est-elle une cible pour l'immunothérapie ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est une cible potentielle pour l'immunothérapie dans le cancer." } }, { "@type": "Question", "name": "Comment l'IL-27 influence-t-elle les traitements ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut influencer l'efficacité des traitements en modulant la réponse immunitaire." } }, { "@type": "Question", "name": "Quelles complications sont liées à l'IL-27 ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent entraîner des complications dans les maladies auto-immunes." } }, { "@type": "Question", "name": "L'IL-27 est-elle impliquée dans des maladies chroniques ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'IL-27 est associée à des maladies chroniques comme l'arthrite et le lupus." } }, { "@type": "Question", "name": "Comment l'IL-27 affecte-t-elle le cancer ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "L'IL-27 peut avoir un rôle double dans le cancer, favorisant ou inhibant la croissance tumorale." } }, { "@type": "Question", "name": "Y a-t-il des risques d'infection liés à l'IL-27 ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des niveaux élevés d'IL-27 peuvent augmenter le risque d'infections en modulant l'immunité." } }, { "@type": "Question", "name": "L'IL-27 est-elle liée à des troubles neurologiques ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des niveaux anormaux d'IL-27 peuvent être associés à des troubles neurologiques comme la sclérose en plaques." } }, { "@type": "Question", "name": "Quels facteurs augmentent l'IL-27 ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Le stress, l'obésité et les infections chroniques peuvent augmenter les niveaux d'IL-27." } }, { "@type": "Question", "name": "L'âge influence-t-il les niveaux d'IL-27 ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les niveaux d'IL-27 peuvent augmenter avec l'âge, affectant la réponse immunitaire." } }, { "@type": "Question", "name": "Les maladies auto-immunes sont-elles un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes atteintes de maladies auto-immunes présentent souvent des niveaux élevés d'IL-27." } }, { "@type": "Question", "name": "Le tabagisme affecte-t-il l'IL-27 ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, le tabagisme peut augmenter les niveaux d'IL-27 et aggraver l'inflammation." } }, { "@type": "Question", "name": "Y a-t-il un lien entre l'IL-27 et l'alimentation ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Certaines habitudes alimentaires peuvent influencer les niveaux d'IL-27, notamment les régimes riches en sucres." } } ] } ] }

Sources (10000 au total)

Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: Differences between terminal and proximal complement inhibition.

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening, acquired disease in which blood cells lacking complement regulatory proteins are destroyed because of uncontrolled complement act...

Complement Inhibition in Paroxysmal Nocturnal Hemoglobinuria (PNH): A Systematic Review and Expert Opinion from Central Europe on Special Patient Populations.

Hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) is complement-mediated due to the lack of complement inhibitors in the hemopoietic cell membranes, making complement inhibition the best approach... The expert recommendations presented here were created using a Delphi-like process by a group of expert PNH specialists across Central Europe. Based on an initial advisory board meeting discussion, re... Using a systematic approach, literature databases were searched for relevant studies, and 50 articles were reviewed by the experts and included as supporting evidence.... Implementation of these recommendations uniformly across healthcare institutions will promote the best use of complement inhibition in managing PNH, and has the potential to positively impact patient ...

Efficacy and safety of the investigational complement C5 inhibitor zilucoplan in patients hospitalized with COVID-19: an open-label randomized controlled trial.

The efficacy and safety of complement inhibition in COVID-19 patients is unclear.... A multicenter randomized controlled, open-label trial. Hospitalized COVID-19 patients with signs of systemic inflammation and hypoxemia (PaO... 81 patients were randomly assigned to zilucoplan (n = 55) or the control group (n = 26). 78 patients were included in the safety and primary analysis. Most were men (87%) and the median age was 63 yea... Administration of zilucoplan to COVID-19 patients in this proof-of-concept randomized trial was well tolerated under antibiotic prophylaxis. While not reaching statistical significance, indicators of ...

Antibiofilm agents with therapeutic potential against enteroaggregative Escherichia coli.

Enteroaggregative Escherichia coli (EAEC) is a predominant but neglected enteric pathogen implicated in infantile diarrhoea and nutrient malabsorption. There are no non-antibiotic approaches to dealin... We used EAEC strains, 042 and MND005E in a medium-throughput crystal violet-based antibiofilm screen. Hits were confirmed in concentration-dependence, growth kinetic and time course assays and activit... In all, five compounds (1.25%) reproducibly inhibited biofilm accumulation by at least one strain by 30-85% while inhibiting growth by under 10%. Hits exhibited potent antibiofilm activity at concentr... This study identified five compounds, not previously described as anti-adhesins or Gram-negative antibacterials, with significant EAEC antibiofilm activity. Molecule, MMV687800 targets the EAEC Aap. I...

Comparative Effectiveness of Pegcetacoplan Versus Ravulizumab and Eculizumab in Complement Inhibitor-Naïve Patients with Paroxysmal Nocturnal Hemoglobinuria: A Matching-Adjusted Indirect Comparison.

In the absence of head-to-head trials, this study compared treatment outcomes with the C3 complement inhibitor pegcetacoplan versus the C5 complement inhibitor eculizumab or ravulizumab in complement ... A matching-adjusted indirect comparison was conducted using individual patient data from the pegcetacoplan arm of the PRINCE trial (NCT04085601; n = 34) and aggregate data from the ravulizumab (n = 12... After weighting, treatment with pegcetacoplan was associated with statistically significant improvements in most clinical endpoints compared with ravulizumab or eculizumab treatment. These included: g... Pegcetacoplan provides clinical benefits as first-line treatment for complement inhibitor-naïve patients with PNH.... ClinicalTrials.gov identifier, NCT04085601....

Prevalence of geographic atrophy in Nordic countries and number of patients potentially eligible for intravitreal complement inhibitor treatment: A systematic review with meta-analyses and forecasting study.

We systematically reviewed the literature on the prevalence of geographic atrophy (GA) in Nordic populations, conducted meta-analyses on age-stratified estimates, and calculated current and future num...

Severe refractory warm autoimmune haemolytic anaemia after the SARS-CoV-2 Pfizer-BioNTech vaccine (BNT162b2 mRNA) managed with emergency splenectomy and complement inhibition with eculizumab.

A male in his teens with a history of liver transplant for biliary atresia (aged 2 years) and autoimmune haemolytic anaemia (AIHA, aged 6 years) presented with jaundice, dark urine, fatigue and chest ...

Improvements in hematologic markers and decreases in fatigue with pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and mild or moderate anemia (hemoglobin ≥10 g/dL) who had received eculizumab or were naive to complement inhibitors.

Although complement component 5 inhibitors (C5is) eculizumab and ravulizumab improve paroxysmal nocturnal hemoglobinuria (PNH) outcomes, patients may experience persistent anemia. This post hoc analys... Patients with PNH and hemoglobin ≥10.0 g/dL at baseline of PADDOCK (N = 6), PRINCE (N = 8), and PEGASUS (N = 11) were included. Before receiving pegcetacoplan, PADDOCK and PRINCE patients were C5i-nai... From baseline to week 16, mean (SD) hemoglobin concentrations increased in C5i-naive patients (PADDOCK: 10.5 [0.4] to 12.7 [1.1] g/dL; PRINCE: 11.3 [1.0] to 14.0 [1.3] g/dL) and those with suboptimal ... Patients with PNH and mild/moderate anemia who were C5i-naive or who had suboptimal hemoglobin concentrations despite eculizumab treatment had improved hematologic outcomes and reduced fatigue after i... Trial registration numbers: PADDOCK (NCT02588833), PRINCE (NCT04085601; EudraCT, 2018-004220-11), PEGASUS (NCT03500549)....